In this regard, afatinib may be a suitable choice for elderly patients with EGFR mutation-positive NSCLC who are receiving multiple concomitant medications, due to its reported low potential for drug–drug interactions, and low exposure to hepatic metabolism and excretion [35]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.